GlassScriptPhysician profile
Brent Herron
NPI 1437544558
$1,328.21
in general payments reported to CMS, 2019-2025
23 companies · $875 in 2025
The $875 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $312 · 2024: $141 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $325.20 | 2025 | Sapien 3 Ultra Resilia, Edwards Sapien Xt Transcatheter Heart Valve (Thv), Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ethicon INC. | $208.71 | 2023 | Monarch Platform |
| Sanofi-Aventis U.S. LLC | $110.82 | 2024-2025 | |
| Boston Scientific Corporation | $99.75 | 2023-2025 | Wavewriter Alpha Prime 16, Watchman |
| Aimmune Therapeutics, INC. | $72.17 | 2024-2025 | Zenpep |
| Ossur Americas, INC. | $51.30 | 2025 | |
| Amgen INC. | $49.08 | 2025 | Krystexxa |
| Abiomed | $41.81 | 2025 | |
| Exact Sciences Corporation | $41.78 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $39.45 | 2025 | Arexvy, Shingrix |
| Abbott Laboratories | $29.44 | 2025 | Eterna |
| Linus Health, INC. | $29.28 | 2024 | Core Cognitive Evaluation |
| Janssen Pharmaceuticals, INC | $28.73 | 2024 | Spravato |
| Alkermes, INC. | $26.53 | 2023 | Aristada, Lybalvi |
| Sonex Health, INC. | $26.17 | 2025 | Sx-One Microknife |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $24.36 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Otsuka America Pharmaceutical, INC. | $22.35 | 2023 | Abilify Maintena, Rexulti |
| Biomerieux INC | $21.71 | 2025 | |
| Lucid Diagnostics INC. | $20.96 | 2024 | |
| Pfizer INC. | $19.78 | 2025 | |
| Novo Nordisk INC | $14.66 | 2025 | Wegovy |
| Lilly USA, LLC | $14.46 | 2023 | Mounjaro |
| Corium, LLC | $9.71 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Herron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.